Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CRHBP | P24387 | 1/20 | 0.44 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.37 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.37 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | TTR | P02766 | 1/20 | 0.37 |
| ▸ | MARS1 | P56192 | 1/20 | 0.37 |
| ▸ | NEK2 | P51955 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1676307 | 0.89 | SUV39H2 (0.41) | NPC1RAB9AKDM4ECRHBPCRHR2 | |
| SCHEMBL1676309 | 0.89 | SUV39H2 (0.41) | NPC1RAB9AKDM4ECRHBPCRHR2 | |
| SCHEMBL1676534 | 0.87 | SUV39H2 (0.41) | NPC1RAB9AKDM4ECRHBPCRHR2 | |
| SCHEMBL1676020 | 0.87 | NPC1 (0.56) | NPC1RAB9AKDM4ECRHBPCRHR2 | |
| SCHEMBL1676279 | 0.86 | SUV39H2 (0.42) | NPC1RAB9AKDM4ECRHBPCRHR2 | |
| SCHEMBL1481919 | 0.84 | NPC1 (0.52) | NPC1RAB9AKDM4ECRHBPCRHR2 | |
| SCHEMBL1676275 | 0.84 | SUV39H2 (0.40) | NPC1RAB9AKDM4ECRHBPCRHR2 | |
| SCHEMBL1481698 | 0.82 | NPC1 (0.47) | NPC1RAB9AKDM4ECRHBPCRHR2 | |
| SCHEMBL1676334 | 0.82 | SUV39H2 (0.41) | NPC1RAB9AKDM4ECRHBPCRHR2 | |
| SCHEMBL1676332 | 0.82 | SUV39H2 (0.41) | NPC1RAB9AKDM4ECRHBPCRHR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092553-A1 | Substituted Azole Derivatives, Compositions, and Methods of Use | TRANSTECH PHARMA, INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110092553-A1 | Substituted Azole Derivatives, Compositions, and Methods of Use | TRANSTECH PHARMA, INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110092553-A1 | Substituted Azole Derivatives, Compositions, and Methods of Use | TRANSTECH PHARMA, INC. (US) | 2011-04-21 | — | — | US | disclosed |
| EP-1730118-A1 | SUBSTITUTED AZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE | Transtech Pharma, Inc. (US) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005080346-A1 | SUBSTITUTED AZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| US-20050187277-A1 | Substituted azole derivatives, compositions, and methods of use | TRANSTECH PHARMA, INC. | 2005-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092553-A1 | Substituted Azole Derivatives, Compositions, and Methods of Use | PTPRO, PTPN5, PTPRE | NPC1 3228/4885RAB9A 3396/4885KDM4E 733/4885 |
| US-20050187277-A1 | Substituted azole derivatives, compositions, and methods of use | PTPRO, PTPN5, PTPRE | NPC1 3228/4885RAB9A 3396/4885KDM4E 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.